EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Triple Therapy with Telmisartan, Amlodipine, and Rosuvastatin (TAR) Versus Telmisartan/Amlodipine (TA) and Telmisartan/Rosuvastatin (TR) Combinations in Hypertension and Dyslipidemia: A Systematic Review and Meta-analysis

Shady Habboush, Navyamani V Kagita, Ahmed F Gadelmawla, Ahmed Elmoursi, Nooraldin Merza, Ahmed A Abdo, Al Hussein M Zahran, Moustafa Eldeib, Alsayed A Almarghany, Mohamed M Abdelfadil, Mohamed A Abdelkarim, Islam Shawky und 4 weitere

High Blood Pressure & Cardiovascular Prevention · 2024

DOI: 10.1007/s40292-024-00689-3 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift High Blood Pressure & Cardiovascular Prevention, 2024. Verfasst von Shady Habboush und 15 weiteren Autor:innen. Beteiligte Einrichtung: Saudi German Hospital in Dubai, Dubai, UAE. Hauptthemen laut MEDLINE: Angiotensin II Type 1 Receptor Blockers, Antihypertensive Agents, Blood Pressure, Calcium Channel Blockers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Hypertension and dyslipidemia are common contributors to cardiovascular disease (CVD), often occurring together. Effectively Managing both is key to reducing mortality and morbidity, but complex regimens reduce adherence. AIM: This study investigated the comparative efficacy and safety of a three-drug regimen (TAR) containing telmisartan, amlodipine, and rosuvastatin against two-drug combinations (TA and TR) for managing hypertension and dyslipidemia. METHODS: We searched PubMed, Web of Science, Cochrane, Embase, and Scopus databases for relevant articles matching our inclusion criteria. Following the application of inclusion criteria, four studies were selected for qualitative analysis and four studies for meta-analysis. RESULTS: Our analysis showed TAR [n = 155] significantly reduced mean systolic blood pressure (MSSBP) at week 4 compared to TR (n = 163) (MD = -15.65 mmHg) and TA (MD = -4.63 mmHg). TAR also showed superiority over all groups (TR [n = 163], TA [n = 162]) in MSSBP reduction. For low-density lipoprotein-cholesterol (LDL-C), TAR only showed a significant difference at week 4 compared to TA (MD = -86.41 mg/dL), with no difference between TAR and TR at either week 4 or 8. CONCLUSION: Our findings suggest that TAR may be a safe and effective therapeutic option for the concurrent management of hypertension and dyslipidemia. However, there is no significant difference regarding adverse events between both arms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin II Type 1 Receptor BlockersAntihypertensive AgentsBlood PressureCalcium Channel BlockersHydroxymethylglutaryl-CoA Reductase InhibitorsHypertensionRosuvastatin CalciumAgedFemaleHumansMaleMiddle AgedAmlodipineBiomarkersDrug CombinationsDrug Therapy, CombinationDyslipidemiasLipidsTelmisartanTime FactorsTreatment Outcome

Stichwörter der Autor:innen

DyslipidemiaHypertensionTARTelmisartan/amlodipine/rosuvastatinTriple therapy

Substanzen

AmlodipineAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsBiomarkersCalcium Channel BlockersDrug CombinationsHydroxymethylglutaryl-CoA Reductase InhibitorsLipidsRosuvastatin CalciumTelmisartan

Autor:innen und Institutionen

  • Saudi German Hospital in Dubai, Dubai, UAE.
  • Department of Internal Medicine, Mercy Catholic Medical Center, Darby, PA, USA.
  • Faculty of Medicine, Menoufia University, Menoufia, Egypt.
  • Department of Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Internal Medicine Department, University of Toledo, Toledo, OH, USA.
  • Department of Cardiology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.

Zitieren

APA

Habboush, S., Kagita, N. V., Gadelmawla, A. F., Elmoursi, A., Merza, N., Abdo, A. A., Zahran, A. H. M., Eldeib, M., Almarghany, A. A., Abdelfadil, M. M., Abdelkarim, M. A., Shawky, I., Mohammed, O. M., Alharran, A., Ali, M. M., & Elbardisy, S. (2024). Triple Therapy with Telmisartan, Amlodipine, and Rosuvastatin (TAR) Versus Telmisartan/Amlodipine (TA) and Telmisartan/Rosuvastatin (TR) Combinations in Hypertension and Dyslipidemia: A Systematic Review and Meta-analysis. High Blood Pressure & Cardiovascular Prevention. https://doi.org/10.1007/s40292-024-00689-3

Vancouver

Habboush S, Kagita NV, Gadelmawla AF, Elmoursi A, Merza N, Abdo AA, et al. Triple Therapy with Telmisartan, Amlodipine, and Rosuvastatin (TAR) Versus Telmisartan/Amlodipine (TA) and Telmisartan/Rosuvastatin (TR) Combinations in Hypertension and Dyslipidemia: A Systematic Review and Meta-analysis. High Blood Pressure & Cardiovascular Prevention. 2024. doi:10.1007/s40292-024-00689-3

BibTeX
@article{Habboush2024,
  author = {Habboush, Shady and Kagita, Navyamani V and Gadelmawla, Ahmed F and Elmoursi, Ahmed and Merza, Nooraldin and Abdo, Ahmed A and Zahran, Al Hussein M and Eldeib, Moustafa and Almarghany, Alsayed A and Abdelfadil, Mohamed M and Abdelkarim, Mohamed A and Shawky, Islam and Mohammed, Omar M and Alharran, Abdullah and Ali, Mahmoud M and Elbardisy, Shereef},
  title = {Triple Therapy with Telmisartan, Amlodipine, and Rosuvastatin (TAR) Versus Telmisartan/Amlodipine (TA) and Telmisartan/Rosuvastatin (TR) Combinations in Hypertension and Dyslipidemia: A Systematic Review and Meta-analysis},
  journal = {High Blood Pressure & Cardiovascular Prevention},
  year = {2024},
  doi = {10.1007/s40292-024-00689-3}
}
Kostenlos starten →